home / stock / ryhty / ryhty news
2023-11-28 19:40:21 ET Ryman Healthcare Limited (RYHTY) Q2 2024 Earnings Call Transcript November 28, 2023 04:00 PM ET Company Participants Richard Umbers - Group CEO Rob Woodgate - former Group CFO David Bennett - Group CFO Conference Call Participants ...
2023-05-19 08:08:55 ET Ryman Healthcare Limited press release ( OTCPK:RYHTY ): FY GAAP EPS of $49.90. Revenue of $570.98M (+12.2% Y/Y). For further details see: Ryman Healthcare Limited GAAP EPS of $49.90, revenue of $570.98M
2023-05-19 01:09:02 ET Ryman Healthcare Limited (RYHTY) Q4 2023 Earnings Conference Call May 18, 2023 06:30 PM ET Company Participants Richard Umbers - Group CEO David Bennett - Group CFO Conference Call Participants Nick Mar - Macquarie Stephen Ridge...
Ryman Healthcare Limited (RYHTY) Q4 2022 Earnings Conference Call May 19, 2022, 06:00 PM ET Company Participants Greg Campbell - Chairman Richard Umbers - Group CEO David Bennett - Group CFO Cameron Holland - CEO, Australia Conference Call Participants Stephen Ridgewell - Craigs Investment Pa...
The following slide deck was published by Ryman Healthcare Limited in conjunction with their 2022 Q2 earnings call. For further details see: Ryman Healthcare Limited 2022 Q2 - Results - Earnings Call Presentation
Ryman Healthcare Limited (RYHTY) Q2 2022 Results Conference Call November 18, 2021 04:00 PM ET Company Participants David Kerr - Chair Richard Umbers - Group CEO David Bennett - Group CFO Cameron Holland - CEO, Australia Conference Call Participants Stephen Ridgewell - Craigs Investment Partn...
Ryman is a great business with low risk of disruption and a growing annuity income stream. We discuss how to think about the real estate capital gains, which we believe is more sustainable than the market thinks, as Ryman uniquely guarantees villagers future health care. The compa...
Original post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
Ryman Healthcare (RYM) delivered FY20 (March-ended) NPAT of $242m, up 6.6% YoY, well below prior November guidance of $250-265m, however the miss appears mainly due to the impact of COVID-19 on its key sales month of March. Sales are improving While April trading was also impacted by Cov...